Effect Of Number Of Prior Lines Versus Prior Regimens In Pts Receiving Trifluridine/ Tipiracil (Tas-102).

720Background: RECOURSE showed that treatment with trifluridine/tipiracil in patients (pts) with refractory metastatic colorectal cancer was associated with significantly improved overall survival (OS) versus placebo. Pts were classified in this analysis according to number of prior regimens of anticancer therapy, i.e. regardless of treatment duration or occurrence of progressive disease (PD). Classification by prior lines of treatment may provide a better appreciation of prognosis than prior regimens. Methods: We performed a post hoc analysis of the RECOURSE population to explore the effect of number of prior lines of treatment vs prior regimens on OS in metastatic disease. We analysed individual pt data (n = 800) and reclassified pts on the basis of prior lines of treatment ( 3). In our analysis, a line of treatment ended with clinical or radiological PD. Adjuvant treatments counted as a line if the pt had had PD within 6 months after the end of treatment. If there was a delay u003e 6 months be...